Synonyms: BMS-790052 | BMS790052 | Daklinza®
daclatasvir is an approved drug (EMA (2014), FDA (2015))
Compound class:
Synthetic organic
Comment: Daclatasvir is an orally available anti-hepatitis C virus (HCV) drug, It is a direct-acting inhibitor of the non-structural protein 5A (NS5A) replication complex of HCV [1]. Blocking NS5A function inhibits viral RNA replication and virion assembly.
|
|
No information available. |
Summary of Clinical Use ![]() |
Daclatasvir is used to treat hepatitis C infection. It is often used in fixed-dose combination with sofosbuvir. EMA and FDA authorisations have been withdrawn or discontinued, but the drug is available in other jurisdictions and is still on the WHO essential medicines list of anti-HCV drugs. |
External links ![]() |
For extended ADME data see the following: Drugs.com European Medicines Agency (EMA) |